Topical Antifungal Treatment for Tinea Cruris

NCT ID: NCT01342315

Last Updated: 2013-08-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

483 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-05-31

Study Completion Date

2012-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine if a topical antifungal cream is safe and effective for the treatment of tinea cruris

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tinea Cruris

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Tinea Cruris, antifungal

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active

Product 33525

Group Type EXPERIMENTAL

33525

Intervention Type DRUG

Daily dosing

Placebo

Product 33525 Placebo

Group Type EXPERIMENTAL

Placebo

Intervention Type DRUG

Daily dosing

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

33525

Daily dosing

Intervention Type DRUG

Placebo

Daily dosing

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* moderate erythema, mild scaling, and moderate pruritis

Exclusion Criteria

* pregnancy and allergies
Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medicis Global Service Corporation

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ron Staugaard

Role: STUDY_DIRECTOR

Medicis Pharmaceutical

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Fremont, California, United States

Site Status

Los Angeles, California, United States

Site Status

Miami, Florida, United States

Site Status

Miramar, Florida, United States

Site Status

St. Petersburg, Florida, United States

Site Status

Evansville, Indiana, United States

Site Status

Warren, Michigan, United States

Site Status

Paramus, New Jersey, United States

Site Status

Albuquerque, New Mexico, United States

Site Status

Cincinnati, Ohio, United States

Site Status

Philadelphia, Pennsylvania, United States

Site Status

Goodletsville, Tennessee, United States

Site Status

Austin, Texas, United States

Site Status

College Station, Texas, United States

Site Status

Plano, Texas, United States

Site Status

San Antonio, Texas, United States

Site Status

Lynchburg, Virginia, United States

Site Status

Belize City, , Belize

Site Status

San Salvador, , El Salvador

Site Status

San Pedro Sula, , Honduras

Site Status

Cidra, , Puerto Rico

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Belize El Salvador Honduras Puerto Rico

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MP-1000-01

Identifier Type: -

Identifier Source: org_study_id